Search research articles
Contact Us
Filters
Showing results (291-300 of 298) with videos related to
Page
of 30
Sort By:
You have reached the last page of results.
This site can display upto 298 results.
Cancer Research
|
December 14, 2017
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms
Costanza Paoletti, Andi K Cani, Jose M Larios, et al.
European Urology
|
August 18, 2024
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response
Nathan M Merrill, Samuel D Kaffenberger, Liwei Bao, et al.
Molecular Oncology
|
December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
Andi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Oncotarget
|
November 23, 2017
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
Daniel H Hovelson, Chia-Jen Liu, Yugang Wang, et al.
Neoplasia (New York, N.Y.)
|
May 1, 2015
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors
Daniel H Hovelson, Andrew S McDaniel, Andi K Cani, et al.
Nature Communications
|
September 15, 2022
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
Thomas C Westbrook, Xiangnan Guan, Eva Rodansky, et al.
Nature Communications
|
June 14, 2020
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Tarek H Mouhieddine, Adam S Sperling, Robert Redd, et al.
Lancet (London, England)
|
June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
Meletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Page
of 30
Search research articles
Search
Showing results (291-300 of 298) with videos related to
Sort By:
Page
of 30
You have reached the last page of results.
This site can display upto 298 results.
Cancer Research
|
December 14, 2017
Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms
Costanza Paoletti, Andi K Cani, Jose M Larios, et al.
European Urology
|
August 18, 2024
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response
Nathan M Merrill, Samuel D Kaffenberger, Liwei Bao, et al.
Molecular Oncology
|
December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection
Andi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Oncotarget
|
November 23, 2017
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy
Daniel H Hovelson, Chia-Jen Liu, Yugang Wang, et al.
Neoplasia (New York, N.Y.)
|
May 1, 2015
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors
Daniel H Hovelson, Andrew S McDaniel, Andi K Cani, et al.
Nature Communications
|
September 15, 2022
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity
Thomas C Westbrook, Xiangnan Guan, Eva Rodansky, et al.
Nature Communications
|
June 14, 2020
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Tarek H Mouhieddine, Adam S Sperling, Robert Redd, et al.
Lancet (London, England)
|
June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
Meletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Page
of 30